These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 28600471)

  • 1. Asymmetric Dimethylarginine Contributes to the Impaired Response to Erythropoietin in CKD-Anemia.
    Yokoro M; Nakayama Y; Yamagishi SI; Ando R; Sugiyama M; Ito S; Yano J; Taguchi K; Kaida Y; Saigusa D; Kimoto M; Abe T; Ueda S; Fukami K
    J Am Soc Nephrol; 2017 Sep; 28(9):2670-2680. PubMed ID: 28600471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease.
    Matsuguma K; Ueda S; Yamagishi S; Matsumoto Y; Kaneyuki U; Shibata R; Fujimura T; Matsuoka H; Kimoto M; Kato S; Imaizumi T; Okuda S
    J Am Soc Nephrol; 2006 Aug; 17(8):2176-83. PubMed ID: 16807406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of adipose tissue asymmetric dimethylarginine/dimethylarginine dimethylaminohydrolase pathway in adipose tissue phenotype and metabolic abnormalities in subtotally nephrectomized rats.
    Minakuchi H; Wakino S; Hosoya K; Sueyasu K; Hasegawa K; Shinozuka K; Yoshifuji A; Futatsugi K; Komatsu M; Kanda T; Tokuyama H; Hayashi K; Itoh H
    Nephrol Dial Transplant; 2016 Mar; 31(3):413-23. PubMed ID: 26516203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease.
    Matsumoto Y; Ueda S; Yamagishi S; Matsuguma K; Shibata R; Fukami K; Matsuoka H; Imaizumi T; Okuda S
    J Am Soc Nephrol; 2007 May; 18(5):1525-33. PubMed ID: 17409314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human recombinant erythropoietin augments serum asymmetric dimethylarginine concentrations but does not compromise nitric oxide generation in mice.
    Desai A; Zhao Y; Warren JS
    Nephrol Dial Transplant; 2008 May; 23(5):1513-20. PubMed ID: 18204093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 Months before the Initiation of Hemodialysis: Comparison of Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator.
    Yoshida T; Hayashi M
    Keio J Med; 2017 Sep; 66(3):44-50. PubMed ID: 27990008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic renal impairment and DDAH2-1151 A/C polymorphism determine ADMA levels in type 2 diabetic subjects.
    Marra M; Marchegiani F; Ceriello A; Sirolla C; Boemi M; Franceschi C; Spazzafumo L; Testa I; Bonfigli AR; Cucchi M; Testa R
    Nephrol Dial Transplant; 2013 Apr; 28(4):964-71. PubMed ID: 23129820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of asymmetric dimethylarginine (ADMA) in glomerular capillary loss and sclerosis in a rat model of chronic kidney disease (CKD).
    Ueda S; Yamagishi S; Matsumoto Y; Kaida Y; Fujimi-Hayashida A; Koike K; Tanaka H; Fukami K; Okuda S
    Life Sci; 2009 Jun; 84(23-24):853-6. PubMed ID: 19351540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Effect of Vitamin D Deficiency on Anemia and Erythropoietin Hyporesponsiveness in Patients of Chronic Kidney Disease.
    Nand N; Mittal R
    J Assoc Physicians India; 2017 Feb; 65(2):38-42. PubMed ID: 28457030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble Fas affects erythropoiesis in vitro and acts as a potential predictor of erythropoiesis-stimulating agent therapy in patients with chronic kidney disease.
    Chiloff DM; de Almeida DC; Dalboni MA; Canziani ME; George SK; Morsi AM; El-Akabawy N; Porada CD; Durao MS; Zarjou A; Almeida-Porada G; Goes MA
    Am J Physiol Renal Physiol; 2020 Apr; 318(4):F861-F869. PubMed ID: 32003597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis.
    Kawahara K; Minakuchi J; Yokota N; Suekane H; Tsuchida K; Kawashima S
    Nephrology (Carlton); 2015 Dec; 20 Suppl 4():29-32. PubMed ID: 26456375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epoetin Beta and C-Terminal Fibroblast Growth Factor 23 in Patients With Chronic Heart Failure and Chronic Kidney Disease.
    Eisenga MF; Emans ME; van der Putten K; Cramer MJ; Diepenbroek A; Velthuis BK; Doevendans PA; Verhaar MC; Joles JA; Bakker SJL; Nolte IM; Braam B; Gaillard CAJM
    J Am Heart Assoc; 2019 Aug; 8(16):e011130. PubMed ID: 31423921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.
    Johnson DW; Pascoe EM; Badve SV; Dalziel K; Cass A; Clarke P; Ferrari P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM;
    Am J Kidney Dis; 2015 Jan; 65(1):49-57. PubMed ID: 25115616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of dimethylarginine dimethylaminohydrolase activity in regulation of tissue and plasma concentrations of asymmetric dimethylarginine in an animal model of prolonged critical illness.
    Davids M; Richir MC; Visser M; Ellger B; van den Berghe G; van Leeuwen PA; Teerlink T
    Metabolism; 2012 Apr; 61(4):482-90. PubMed ID: 22000584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methoxy Polyethylene Glycol-Epoetin Beta as a Novel Erythropoiesis Stimulating Agent with Possible Nephroprotective and Cardiovascular Protective Effects in Non-Dialysis Chronic Kidney Disease Patients.
    Piotr B; Mariusz S; Jacek R
    Curr Pharm Biotechnol; 2017; 18(4):303-308. PubMed ID: 28137221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the endogenous nitric oxide inhibitor asymmetric dimethylarginine (ADMA) and brain-derived neurotrophic factor (BDNF) in depression and behavioural changes: clinical and preclinical data in chronic kidney disease.
    Kielstein H; Suntharalingam M; Perthel R; Song R; Schneider SM; Martens-Lobenhoffer J; Jäger K; Bode-Böger SM; Kielstein JT
    Nephrol Dial Transplant; 2015 Oct; 30(10):1699-705. PubMed ID: 26175142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease.
    Emrich IE; Zawada AM; Martens-Lobenhoffer J; Fliser D; Wagenpfeil S; Heine GH; Bode-Böger SM
    Clin Res Cardiol; 2018 Mar; 107(3):201-213. PubMed ID: 29101459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversible sequestration of nitric oxide by hemoglobin during hemodialysis in end-stage renal disease.
    Kang ES; Miles DE; Tevlin MT; Cates TB; Acchiardo SR
    Am J Med Sci; 2001 Feb; 321(2):113-23. PubMed ID: 11217813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
    Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
    Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with erythropoiesis-stimulating agents in chronic kidney disease patients with cancer.
    Hazzan AD; Shah HH; Hong S; Sakhiya V; Wanchoo R; Fishbane S
    Kidney Int; 2014 Jul; 86(1):34-9. PubMed ID: 24402094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.